23:34 , Nov 2, 2017 |  BC Innovations  |  Targets & Mechanisms

Golden State of DUBs

Four papers in the last two weeks describing inhibitors of the ubiquitin-regulating protein USP7 could signal an important breakthrough in the ability to drug DUBs, a class of enzymes that has been stubbornly intractable until...
00:28 , Mar 31, 2017 |  BC Innovations  |  Targets & Mechanisms

Cells on the rise

This year’s meeting of the American Association for Cancer Research (AACR) will keep the spotlight on immuno-oncology, where preclinical science is continuing to expand the use of different types of innate and adaptive immune cells...
08:00 , Feb 1, 2016 |  BioCentury  |  Emerging Company Profile

Degradation by Degronimid

C4 Therapeutics Inc. has found a way to harness the ubiquitin-proteasome pathway for targeted protein degradation. The company's Degronimid platform uses small molecules to tether disease-associated proteins to ubiquitin, triggering their degradation by the proteasome. ...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Dollars for degradation

C4 Therapeutics Inc. parlayed strong preclinical data into a tranched $73 million series A round and a deal with Roche (SIX:ROG; OTCQX:RHHBY) that will allow the newco to pursue several indications with its protein degradation...
02:21 , Jan 8, 2016 |  BC Extra  |  Financial News

C4 debuts with $73M, Roche deal

C4 Therapeutics Inc. (Cambridge, Mass.) debuted with a $73 million series A round, a discovery deal with Roche (SIX:ROG; OTCQX:RHHBY) and an exclusive, worldwide license from the Dana-Farber Cancer Institute (Boston, Mass.) to the Degronimid...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Company News

Almac, Genentech, Roche deal

Almac’s Almac Discovery oncology subsidiary granted Roche’s Genentech unit exclusive, worldwide rights to develop and commercialize a preclinical ubiquitin-specific protease inhibitor. Genentech plans to develop the inhibitor for cancer and will be responsible for development,...
07:00 , Jun 22, 2015 |  BioCentury  |  Strategy

Two great tastes

After spending several years on fundamental biology research on the ubiquitin-protease system, Genentech Inc. has found a partner with the chemistry and compounds needed to move the work forward in both the lab and the...
02:10 , Jun 16, 2015 |  BC Extra  |  Company News

Almac, Genentech enter cancer collaboration

The Almac Discovery oncology subsidiary of Almac Group Ltd. (Craigavon, U.K.) granted the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) development and commercialization rights to its preclinical ubiquitin-specific protease inhibitors. Genentech will be responsible for...
08:00 , Dec 22, 2014 |  BC Week In Review  |  Company News

Almac sales and marketing update

Almac launched a CLIA-validated, next-generation sequencing test for p53 mutations that runs on formalin-fixed, paraffin-embedded (FFPE) samples. The diagnostic has been developed using technology from Illumina Inc. (NASDAQ:ILMN, San Diego, Calif.). Almac Group...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Clinical News

ALM AADx: Clinical trial data

Data from a validation study analyzing 283 samples from patients with high-grade serous ovarian cancer showed that Almac’s ALM AADx assay identified a subgroup of patients with a better prognosis for OS following standard chemotherapy...